--- schema_version: "secwatch.filing_event.v1" accession: "0001493152-26-028283" form_type: "8-K" ticker: "AIM" cik: "0000946644" company_name: "AIM ImmunoTech Inc." filed_at: "2026-06-11T20:15:23+00:00" generated_at: "2026-06-11T20:27:43.279676+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.7 calibrated_materiality_score: 0.7 confidence: "high" source: SEC EDGAR --- # AIM ImmunoTech prices $2.65 million registered direct offering and private placement ## Summary - Company issued 2,554,119 registered shares and 771,503 unregistered shares at $0.5189 per share for gross proceeds of ~$2.65M. - Also issued pre-funded warrants for 1,782,616 shares at $0.001 exercise price and Class J warrants for 10,216,476 shares at $0.5189. - Offering includes placement agent warrants for 306,494 shares at $0.6486 per share; Ladenburg Thalmann acted as placement agent. - Net proceeds will fund clinical trial activities, manufacture of clinical drug supply, and working capital. - Closing expected on or about June 10, 2026, subject to customary conditions. ## SEC filing metadata - accession: 0001493152-26-028283 - form_type: 8-K - ticker: AIM - cik: 0000946644 - company_name: AIM ImmunoTech Inc. - filed_at: 2026-06-11T20:15:23+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.7 - calibrated_materiality_score: 0.7 - confidence: high - sec_items: 1.01, 3.02, 8.01, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/946644/000149315226028283/0001493152-26-028283-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946644/000149315226028283/form8-k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001493152-26-028283 - JSON: https://secwatch.observer/filing/0001493152-26-028283.json - Plain text: https://secwatch.observer/filing/0001493152-26-028283.txt ## Key facts - Equity Issuances AIM ImmunoTech Inc. issued up to 1,782,616 shares of Common Stock of warrant to institutional investors. - Security: warrant - Shares: up to 1,782,616 shares of Common Stock - Purchaser: institutional investors source text: pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 1,782,616 shares of Common Stock (the “Pre-Funded Warrant Shares”) at an exercise price of $0.001 evidence_url: https://www.sec.gov/Archives/edgar/data/946644/000149315226028283/0001493152-26-028283-index.htm - Equity Issuances AIM ImmunoTech Inc. issued 771,503 shares of common stock to institutional investors for $0.5189 per share. - Security: common stock - Shares: 771,503 shares - Purchaser: institutional investors - Consideration: $0.5189 per share source text: the Company also agreed to issue and sell to such Investors, in a concurrent private placement, 771,503 shares of Common Stock at a per share price of $0.5189 (the “Unregistered Shares”) evidence_url: https://www.sec.gov/Archives/edgar/data/946644/000149315226028283/0001493152-26-028283-index.htm - Equity Issuances AIM ImmunoTech Inc. issued 306,494 shares of Common Stock of warrant to Ladenburg Thalmann & Co. Inc.. - Security: warrant - Shares: 306,494 shares of Common Stock - Purchaser: Ladenburg Thalmann & Co. Inc. source text: The Company also agreed to issue to the Placement Agent warrants (the “Placement Agent Warrants”) to purchase 306,494 shares of Common Stock (the “Placement Agent Warrant Shares”) evidence_url: https://www.sec.gov/Archives/edgar/data/946644/000149315226028283/0001493152-26-028283-index.htm - Equity Issuances AIM ImmunoTech Inc. issued up to 10,216,476 shares of Common Stock of warrant to institutional investors. - Security: warrant - Shares: up to 10,216,476 shares of Common Stock - Purchaser: institutional investors source text: Class J warrants (the “Class J Warrants”) to purchase up to 10,216,476 shares of Common Stock (the “Class J Warrant Shares”), at an exercise price of $0.5189 per share evidence_url: https://www.sec.gov/Archives/edgar/data/946644/000149315226028283/0001493152-26-028283-index.htm - Material Agreements AIM ImmunoTech Inc. entered into Securities Purchase Agreement with institutional investors valued at Gross proceeds of approximately $1.3 million from Registered Offering, plus potential additional gro (effective 2026-06-09). - Action: entry - Agreement: equity purchase - Counterparty: institutional investors - Value: Gross proceeds of approximately $1.3 million from Registered Offering, plus potential additional gro - Effective: 2026-06-09 source text: On June 9, 2026, AIM ImmunoTech Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell to such investors in a registered direct offering 2,554,119 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company, at an offering price of $0.5189 per share (such registered direct offering, the “Registered Offering”). evidence_url: https://www.sec.gov/Archives/edgar/data/946644/000149315226028283/0001493152-26-028283-index.htm - Material Agreements AIM ImmunoTech Inc. entered into Placement Agency Agreement with Ladenburg Thalmann & Co. Inc. valued at Cash fee equal to 8.0% and management fee equal to 0.75% of aggregate gross proceeds of Offerings, p (effective 2026-06-09). - Action: entry - Agreement: underwriting - Counterparty: Ladenburg Thalmann & Co. Inc. - Value: Cash fee equal to 8.0% and management fee equal to 0.75% of aggregate gross proceeds of Offerings, p - Effective: 2026-06-09 source text: In connection with the Offerings, the Company also entered into a placement agency agreement, dated June 9, 2026 (the “Placement Agency Agreement”), with Ladenburg Thalmann & Co. Inc. (the “Placement Agent”), pursuant to which the Company agreed to pay the Placement Agent a cash fee equal to 8.0%, and a management fee equal to 0.75%, of the aggregate gross proceeds of the Offerings, and reimbursed the Placement Agent for certain expenses and legal fees. evidence_url: https://www.sec.gov/Archives/edgar/data/946644/000149315226028283/0001493152-26-028283-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.